Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%
Mark T Bergmann,1 Jon I Williams,2 Paul J Gomes3On behalf of the Bepotastine Besilate Ophthalmic Solutions Clinical Study Group 1Eye Care Associates of Greater Cincinnati, Inc., Cincinnati, OH, USA; 2Bausch + Lomb, Irvine, CA, USA; 3Ora, Inc., Andover, MA, USA Purpose: To examine the pooled per-p...
Guardado en:
Autores principales: | Bergmann MT, Williams JI, Gomes PJ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/798c0d527ea34510a607b2cc370529cb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference
por: McCabe CF, et al.
Publicado: (2012) -
Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis
por: Jeremy B Wingard, et al.
Publicado: (2011) -
Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
por: Patricia B Williams, et al.
Publicado: (2010) -
Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
por: Chigbu DI, et al.
Publicado: (2015) -
Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra RP, et al.
Publicado: (2019)